AR and neoplasm: With this composition, 10 μM of the present PROTAC was demonstrated in HeLa cells—human cervical carcinoma cells transiently expressing the androgen receptor—to be able to permeate cell membranes, binding simultaneously to MDM2 and to the target, AR, promoting the ubiquitination of the latter, and, consequently, its intracellular degradation, verifying a reduction in the levels of this target protein [20], which is known to promote the growth of tumor cells in the prostate [76].